Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
All content for HealthTech Israel Podcast is the property of Chen Sirkis and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
Alon Ben-Noon, Co-founder and CEO, NeuroSense Therapeutics.
HealthTech Israel Podcast
37 minutes
3 years ago
Alon Ben-Noon, Co-founder and CEO, NeuroSense Therapeutics.
Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
HealthTech Israel Podcast
Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
